Suzhou Zelgen Biopharmaceuticals Co.,ltd
Clinical trials sponsored by Suzhou Zelgen Biopharmaceuticals Co.,ltd, explained in plain language.
-
New hope for lung cancer patients after failed treatments
Disease control Recruiting nowThis study is testing the safety and early effectiveness of a new two-drug combination (ZG005 plus gecacitinib) for people with advanced non-small cell lung cancer. It is for patients whose cancer has continued to grow despite previous immunotherapy. The goal is to see if this co…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Apr 01, 2026 23:26 UTC
-
New drug duo enters human trials for Tough-to-Treat cancers
Disease control Recruiting nowThis study is testing whether a new combination of two drugs, ZG006 and ZG005, is safe and effective for people with advanced small cell lung cancer or neuroendocrine carcinoma. It will involve about 350 adult participants to see if the drug combo can shrink tumors and control th…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for tough cancers: early trial tests ZG006 drug
Disease control Recruiting nowThis early-stage study is testing a new drug called ZG006 for people with advanced small cell lung cancer or neuroendocrine carcinoma who have no standard treatments left or cannot tolerate them. The main goals are to find a safe dose, check for side effects, and see if the drug …
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New drug duo tested for Tough-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new combination of two drugs, ZGGS18 and ZG005, for people with advanced solid tumors that have not responded to standard treatments. The main goals are to find the safest and most effective dose and to see if the treatment can shrink tumors. T…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New drug combo trial offers hope for lymphoma patients who stopped responding to standard treatments
Disease control Recruiting nowThis study is testing a new two-drug combination (ZG005 and gecacitinib) for people with lymphoma that has returned or hasn't responded to previous treatments. The first part aims to find a safe and effective dose, while the second part will measure how well the combination works…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New drug duo tested in fight against advanced cervical cancer
Disease control Recruiting nowThis study is testing a new combination of two drugs, ZG005 and gecacitinib, for women with advanced cervical cancer that has spread or returned. The main goals are to find a safe dose and see if the treatment can shrink tumors. It will involve about 120 participants to gather in…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New drug trial offers hope for Tough-to-Treat lung cancer patients
Disease control Recruiting nowThis study is testing whether an experimental drug called ZG006 helps people with relapsed small cell lung cancer live longer than standard chemotherapy. The trial will enroll 420 adults whose cancer has returned after previous treatment. Researchers will directly compare ZG006 a…
Phase: PHASE3 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New drug trial offers hope for Tough-to-Treat cancers
Disease control Recruiting nowThis study is testing whether the experimental drug ZG005 can help control advanced solid tumors in people who haven't responded to standard treatments. The trial will enroll 100 adults with various advanced cancers to see how well the drug works and how safe it is. Researchers w…
Phase: PHASE2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
New hope for tough cancers: early trial tests promising drug
Disease control Recruiting nowThis study is testing a new drug called ZG006 for people with advanced small cell lung cancer or other neuroendocrine cancers. The first part aims to find a safe dose, and the second part will see how well the drug works at controlling the cancer. Researchers will measure how man…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC
-
New cancer drug enters human testing
Disease control Recruiting nowThis is an early-stage study to find a safe dose and see how the body handles a new drug called ZGGS18. It is for people with advanced solid tumors who have no other standard treatments left. The main goals are to check for side effects and see how the drug moves through the body…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC